SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding.
When a patent application is published and until the patent is granted, the Indian Patents Act, 1970, under section 25(1), allows any person to oppose…
11.01.2022 - The Allowed Claims include Composition of FT-104, which is a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPTTORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) - Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ( Field Trip ), a global . Seite 1
The Israeli-based medicinal cannabis company, Kanabo Group, said a wholly-owned subsidiary of Materia, Materia Malta, has commenced sales in Europe of the first medical cannabis flower produced at its EU GMP certified manufacturing site named ‘Carbasi Verde.’
Kanabo announced its proposed acquisition of Materia, a European-focused medical cannabis and CBD company, as well as its European businesses, back in July 2021.